1. Possible Role of Gut Microbiota Alterations in Myocardial Fibrosis and Burden of Heart Failure in Hypertensive Heart Disease.
- Author
-
Pitt B and Diez J
- Subjects
- Humans, Dysbiosis microbiology, Dysbiosis complications, Animals, Gastrointestinal Microbiome physiology, Heart Failure microbiology, Heart Failure physiopathology, Hypertension complications, Fibrosis, Myocardium pathology, Myocardium metabolism
- Abstract
Epidemiological studies have revealed that hypertensive heart disease is a major risk factor for heart failure, and its heart failure burden is growing rapidly. The need to act in the face of this threat requires first an understanding of the multifactorial origin of hypertensive heart disease and second an exploration of new mechanistic pathways involved in myocardial alterations critically involved in cardiac dysfunction and failure (eg, myocardial interstitial fibrosis). Increasing evidence shows that alterations of gut microbiota composition and function (ie, dysbiosis) leading to changes in microbiota-derived metabolites and impairment of the gut barrier and immune functions may be involved in blood pressure elevation and hypertensive organ damage. In this review, we highlight recent advances in the potential contribution of gut microbiota alterations to myocardial interstitial fibrosis in hypertensive heart disease through blood pressure-dependent and blood pressure-independent mechanisms. Achievements in this field should open a new path for more comprehensive treatment of myocardial interstitial fibrosis in hypertensive heart disease and, thus, for the prevention of heart failure., Competing Interests: Disclosures B. Pitt reports being a consultant for Bayer, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lexicon, CEVA Animale, Anacardia, Corteria Therapeutics, and SC Vifor (Relypsa). B. Pitt has stock options in Pharmaceuticals, SQ Innovations, G3 Pharmaceuticals, KBP Biosciences, Sarfez, Cereno Scientific, and Brainstorm Medical. B. Pitt has stocks in SeaStar Medical, Cereno Scientific, and Protonintel. US patent 9931412 site-specific delivery of eplerenone to the myocardium. US patent pending 63/045783 Histone Modulating Agents for the Prevention and Treatment of Organ Injury. Data Safety Monitoring Board: Millennial Pharmaceutics (Lorundrostat). J. Diez reports no conflicts.
- Published
- 2024
- Full Text
- View/download PDF